Get the Stockscreener App
127.34
1.91%
-2.48
After Hours:
127.00
-0.34
-0.27%
Guardant Health Inc stock is traded at $127.34, with a volume of 2.67M.
It is down -1.91% in the last 24 hours and up +34.16% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$129.82
Open:
$130.19
24h Volume:
2.67M
Relative Volume:
1.23
Market Cap:
$16.89B
Revenue:
$1.08B
Net Income/Loss:
$-433.19M
P/E Ratio:
-37.45
EPS:
-3.4004
Net Cash Flow:
$-225.09M
1W Performance:
-2.14%
1M Performance:
+34.16%
6M Performance:
+27.34%
1Y Performance:
+158.30%
1-Day Range:
$126.77
$133.11
1-Week Range:
$126.77
$135.00
52-Week Range:
$40.35
$135.00
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
127.34 | 17.21B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
472.63 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
181.35 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
573.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
128.34 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
360.54 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
[Form 4] Guardant Health, Inc. Insider Trading Activity - Stock Titan
GH (GH) affiliate Kumud Kalia notifies proposed sale of 5,000 shares - Stock Titan
GH (NASDAQ: GH) amendment: affiliate sold 5,000 shares for $652,030 - Stock Titan
Kumud Kalia sells shares; GH (NASDAQ: GH) Form 144 lists dates and proceeds - Stock Titan
The Technical Signals Behind (GH) That Institutions Follow - Stock Traders Daily
Guardant Health Inc. (NASDAQ:GH) Shines as a Top Minervini Trend Template and High Growth Momentum Pick - ChartMill
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook - Kavout
Guardant rated new outperform at RBC on catalysts, growth prospects - MSN
Top Guardant Health Executive Makes Major Insider Move - TipRanks
Guardant Health CIO Kalia sells $652,030 in company stock By Investing.com - Investing.com Australia
Guardant Health CIO Kalia sells $652,030 in company stock - Investing.com
Insider Sell: Kumud Kalia Sells 5,000 Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health Chief Information Officer Sold Shares Worth Over $652K - TradingView
Guardant Health (GH) CIO Kumud Kalia sells 5,000 shares in open market - Stock Titan
Guardant Health (GH) Receives Outperform Rating from RBC Capital Markets - GuruFocus
Guardant Health rated new Outperform at RBC (GH:NASDAQ) - Seeking Alpha
Guardant Health Set to Benefit From Genomic Profiling Growth, RBC Says - Moomoo
RBC Capital Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $185 - Moomoo
RBC Capital Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $185 - Moomoo
RBC Capital initiates Guardant Health stock coverage with outperform rating - Investing.com
RBC Capital initiates Guardant Health stock coverage with outperform rating By Investing.com - Investing.com Canada
GH Receives FDA Approval for Guardant360 CDx as Companion Diagno - GuruFocus
Guardant Health wins FDA approval for HER2 lung cancer test By Investing.com - Investing.com Australia
Guardant Health wins FDA approval for HER2 lung cancer test - Investing.com
Guardant Health, Inc. Announces FDA Approval Of Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim?s HERNEXEOS - marketscreener.com
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS - The Joplin Globe
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health co-CEO Helmy Eltoukhy sells $12.6m in stock By Investing.com - Investing.com South Africa
Guardant Health Insider Sold Shares Worth $12,629,969, According to a Recent SEC Filing - Moomoo
Insider Sell: Michael Bell Sells 2,000 Shares of Guardant Health Inc (GH) - GuruFocus
GH Maintained by Mizuho -- Price Target Raised to $175 - GuruFocus
Guardant Health CFO Michael Bell sells $257,240 in company shares By Investing.com - Investing.com Nigeria
Guardant Health co-CEO Helmy Eltoukhy sells $12.6m in stock - Investing.com India
Guardant Health CFO Michael Bell sells $257,240 in company shares - Investing.com
Guardant Health (NASDAQ: GH) co-CEO’s trust sells 100,000 shares in open market - Stock Titan
Guardant Health (GH) CFO sells 2,000 shares in open-market trade - Stock Titan
HHS indicates skepticism on international cancer risk assessments - Seeking Alpha
Mizuho raises Guardant Health stock price target to $175 on FDA approval By Investing.com - Investing.com South Africa
Mizuho raises Guardant Health stock price target to $175 on FDA approval - Investing.com Canada
Why Grail Could Be the Sleeper Stock Everyone's About to Notice - The Motley Fool
Guardant Health, Inc. (GH) Stock Analysis: Navigating a 9.14% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Goldman Sachs Initiates Guardant Health(GH.US) With Buy Rating, Announces Target Price $165 - Moomoo
Insider Sale: Director at $GH Sells 9,294 Shares - Moomoo
Insider Sell: Steve Krognes Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health director Steve Krognes sells $1.23m in stock By Investing.com - Investing.com South Africa
Guardant Health director Steve Krognes sells $1.23m in stock - Investing.com
Guardant Health (NASDAQ: GH) director sells 9,294 shares in open-market trade - Stock Titan
Guardant Health, Inc. (GH) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
GH Initiates Coverage On Goldman Sachs -- Rating Set to Buy - GuruFocus
GH (Nasdaq) Form 144: Brokered RSU sale schedule via Stifel Nicolaus - Stock Titan
Guardant Health (NASDAQ: GH) Form 144: 2,000 shares listed, 3,000 sold - Stock Titan
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):